The biotech firm projects 2026 revenue between $560M and $585M while planning to launch a clinical trial for MDX3001 by early 2027.
OPKO Health announced a 2026 revenue guidance range of $560M to $585M during its Q2 2026 earnings call. The company highlighted progress in operational efficiency and pipeline development as key drivers for the outlook.
Management noted advancements in its product pipeline, including plans to initiate a clinical trial for MDX3001 by the end of 2026 or early 2027. The guidance follows efforts to improve profitability and streamline operations in recent quarters.
No immediate market reaction was disclosed in the call. The revenue projection aligns with ongoing strategic initiatives to expand its therapeutic portfolio.